E-LIB Suche - Ergebnisse für: Gordon, Kenneth B.

1

Residual Lesional Gene Expression in Psoriasis Patients wit..:

Blauvelt, Andrew ; Gordon, Kenneth B. ; Langley, Richard G....
Journal of Investigative Dermatology. , 2024

2

Bimekizumab 3-year Maintenance of Response in Week 16 Respo..:

Thaçi, Diamant ; Armstrong, April ; Gordon, Kenneth B...
SKIN The Journal of Cutaneous Medicine. 8 (2024) 1 - p. s306 , 2024

Link: https://doi.org/10.25251..

3

Spesolimab treatment for the prevention of flares in people..:

Morita, Akimichi ; Strober, Bruce ; Burden, A David...
Future Rare Diseases. 4 (2024) 1 - p. , 2024

Link: https://doi.org/10.2217/..

4

Deucravacitinib in moderate‐to‐severe plaque psoriasis: Poo..:

Strober, Bruce ; Blauvelt, Andrew ; Warren, Richard B....
Journal of the European Academy of Dermatology and Venereology. , 2024

Link: https://doi.org/10.1111/..

5

Efficacy and safety of subcutaneous spesolimab for the prev..:

Morita, Akimichi ; Strober, Bruce ; Burden, A David...
The Lancet. 402 (2023) 10412 - p. 1541-1551 , 2023

Link: https://doi.org/10.1016/..

6

43758 Bimekizumab safety and tolerability in patients with ..:

Gordon, Kenneth B. ; Gooderham, Melinda ; Foley, Peter...
Journal of the American Academy of Dermatology. 89 (2023) 3 - p. AB22 , 2023

Link: https://doi.org/10.1016/..

7

Next Generation PDE4 Inhibitors that Selectively Target PDE..:

Blauvelt, Andrew ; Langley, Richard G. ; Gordon, Kenneth B....
Dermatology and Therapy. 13 (2023) 12 - p. 3031-3042 , 2023

Link: https://doi.org/10.1007/..

8

Deucravacitinib versus placebo and apremilast in moderate t..:

Strober, Bruce ; Thaçi, Diamant ; Sofen, Howard...
Journal of the American Academy of Dermatology. 88 (2023) 1 - p. 40-51 , 2023

Link: https://doi.org/10.1016/..

9

Deucravacitinib in plaque psoriasis: 2-year laboratory resu..:

Korman, Neil J. ; Passeron, Thierry ; Gordon, Kenneth B....
SKIN The Journal of Cutaneous Medicine. 7 (2023) 2 - p. s119 , 2023

Link: https://doi.org/10.25251..

10

Bimekizumab safety in patients with moderate-to-severe plaq..:

Gordon, Kenneth B ; Langley, Richard G ; Warren, Richard B...
British Journal of Dermatology. 190 (2023) 4 - p. 477-485 , 2023

Link: https://doi.org/10.1093/..

11

Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk ..:

Strober, Bruce ; Thaçi, Diamant ; Sofen, Howard...
Immunotherapy. 15 (2023) 11 - p. 787-797 , 2023

Link: https://doi.org/10.2217/..

12

Bimekizumab safety in patients with moderate to severe plaq..:

Gordon, Kenneth B ; Langley, Richard G ; Warren, Richard B...
SKIN The Journal of Cutaneous Medicine. 6 (2022) 6 - p. s66 , 2022

Link: https://doi.org/10.25251..

13

Efficacy of Risankizumab versus Secukinumab in Patients wit..:

Crowley, Jeffrey J. ; Langley, Richard G. ; Gordon, Kenneth B....
Dermatology and Therapy. 12 (2022) 2 - p. 561-575 , 2022

Link: https://doi.org/10.1007/..

14

34914 Long-term safety of risankizumab in patients with pso..:

Gordon, Kenneth B. ; Blauvelt, Andrew ; Bachelez, Hervé
Journal of the American Academy of Dermatology. 87 (2022) 3 - p. AB78 , 2022

Link: https://doi.org/10.1016/..

15

31085 Bimekizumab early treatment response translates into ..:

Gordon, Kenneth B. ; Sebastian, Michael ; Feldman, Steven R.
Journal of the American Academy of Dermatology. 87 (2022) 3 - p. AB24 , 2022

Link: https://doi.org/10.1016/..